Zacks Investment Research cut shares of ObsEva (NASDAQ:OBSV) from a buy rating to a hold rating in a research note released on Tuesday morning.
According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “
Several other equities analysts have also recently weighed in on the company. HC Wainwright set a $25.00 price objective on ObsEva and gave the stock a buy rating in a research report on Thursday, December 14th. BMO Capital Markets began coverage on ObsEva in a research report on Monday, December 4th. They set an outperform rating and a $20.00 price objective for the company. Royal Bank of Canada reissued a buy rating and set a $22.00 price objective on shares of ObsEva in a research report on Thursday, November 2nd. Finally, Credit Suisse Group began coverage on ObsEva in a research report on Monday, October 9th. They set an outperform rating and a $16.00 price objective for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $19.00.
ObsEva (NASDAQ:OBSV) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.01). ObsEva’s revenue for the quarter was up NaN% on a year-over-year basis. equities analysts anticipate that ObsEva will post -2.26 EPS for the current year.
A number of institutional investors have recently bought and sold shares of the business. Iguana Healthcare Management LLC raised its holdings in ObsEva by 66.7% in the 3rd quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock valued at $407,000 after acquiring an additional 20,000 shares in the last quarter. Abingworth LLP acquired a new position in ObsEva in the 3rd quarter valued at approximately $3,480,000. VHCP Management II LLC raised its holdings in ObsEva by 834.2% in the 3rd quarter. VHCP Management II LLC now owns 1,401,343 shares of the company’s stock valued at $11,407,000 after acquiring an additional 1,251,343 shares in the last quarter. Sphera Funds Management LTD. raised its holdings in ObsEva by 12.4% in the 3rd quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock valued at $2,118,000 after acquiring an additional 28,700 shares in the last quarter. Finally, Sectoral Asset Management Inc raised its holdings in ObsEva by 181.9% in the 2nd quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock valued at $1,820,000 after acquiring an additional 137,331 shares in the last quarter. 35.91% of the stock is owned by hedge funds and other institutional investors.
WARNING: “ObsEva (OBSV) Downgraded by Zacks Investment Research” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/23/obseva-obsv-downgraded-by-zacks-investment-research.html.
ObsEva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about ObsEva? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ObsEva and related companies.